Prescription Drug Recall: Cinacalcet Tablets for N-nitroso Impurity
Dr. Reddy's Laboratories is recalling Cinacalcet 90 mg tablets due to N-nitroso impurity exceeding FDA limits. Patients should contact their healthcare provider.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for manufacturing impurity (N-nitroso Cinacalcet) exceeding regulatory limits. While no illnesses have been reported, N-nitroso compounds are regulatory concerns; the Class II designation reflects FDA's determination of potential health risk from the manufacturing defect.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling Cinacalcet 90 mg tablets in 30-count bottles due to a manufacturing issue identified during quality control.
The recall was triggered because certain lots contain N-nitroso Cinacalcet impurity at levels above the FDA's recommended interim limit. The impurity resulted from a Current Good Manufacturing Practice (CGMP) deviation during production.
The recall affects 10,584 bottles distributed nationwide. The affected lots are T2201443 (expiration March 2025) and T2300664 (expiration December 2025), identified by NDC 43598-369-30.
Patients currently taking Cinacalcet from these lots should contact their healthcare provider to discuss their medication. Healthcare providers should check inventory against the lot numbers and remove affected units from distribution. The FDA classified this as a Class II recall.
The recalled product
- Product
- CINACALCET (CINACALCET)
- Brand
- CINACALCET
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Category
- Drug
- Affected units
- 10,584
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot# T2201443
- Exp 03/2025
- T2300664
- Exp 12/2025.
UPCs (1)
- 0343598369303
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Dr. Reddy's Laboratories, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same brand · CINACALCET
- HighCinacalcet Tablets Recalled for N-Nitroso Impurity Exceeding Limits
FDA (Drugs) · 2026-07-08
- SevereCinacalcet Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2026-07-08
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighCipla cinacalcet 90 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 60 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
Same manufacturer · Dr. Reddy's Laboratories, Inc.
See all →- ModerateVarenicline tablets recalled after an assay value fell below specification
FDA (Drugs) · 2025-12-17
- Moderate
- HighOmeprazole capsule bottle contained a foreign divalproex sodium tablet
FDA (Drugs) · 2025-07-23
- SevereLevetiracetam Injection Label Mismatch Nationwide Recall
FDA (Drugs) · 2025-04-23
- ModerateFDA Recalls JAVYGTOR Tablets Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-12-18
Same hazard · n nitroso impurity
See all →- ModerateDuloxetine delayed-release capsules recalled for N-nitroso impurity contamination
FDA (Drugs) · 2026-05-13
- ModerateFurosemide tablets recalled for presence of N-nitroso impurity
FDA (Drugs) · 2026-04-29
- SevereFluoxetine Tablets 20 mg Recalled for N-Nitroso Impurity
FDA (Drugs) · 2025-06-11
- SevereCarvedilol Tablets Recalled Due to N-Nitroso Impurity
FDA (Drugs) · 2025-06-04
- HighDuloxetine Delayed-Release Capsules Recalled for N-Nitroso Impurity Above Safe Levels
FDA (Drugs) · 2025-03-26